A 44-year-old man presents to the hospital with generalized abdominal pain, malaise, subjective low-grade fever, and a bruise on his left shin. He has an extensive medical history including HIV, hypertension, diabetes, and GERD, but he denies vomiting or diarrhea.
Analysis of 2 phase 3 clinical trials evaluating the safety/efficacy of glecaprevir/pibrentasvir in people with HCV coinfected with HIV-1 found an overall sustained virologic response of 98% at week 12 of treatment in those with or without cirrhosis.
A combination single tablet once-a-day regimen of doravirine/lamivudine/tenofovir disoproxil fumarate demonstrated non-inferiority and no significant adverse events when compared with continuation of established antiretroviral therapy in adults infected with HIV-1.
Compared with uninfected individuals, people with HIV controlled with combination antiretroviral therapy are not at increased risk of developing thyroid dysfunction.